<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697788</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-001264/1;MGH</org_study_id>
    <nct_id>NCT00697788</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients</brief_title>
  <official_title>Cardiovascular Safety of Dexmedetomidine in Pediatric Burn Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care
      units. We are studying whether this drug is cardiovascularly safe in pediatric patients who
      have recently been burned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine
      bolus/infusions in acutely burned pediatric patients. The study entails a bolus of
      dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters
      including EKG, heart rate, oxygen saturation, blood pressure, are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2007</start_date>
  <completion_date type="Actual">December 30, 2008</completion_date>
  <primary_completion_date type="Actual">December 30, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Mean Arterial Pressure (MAP)</measure>
    <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
    <description>Looking at hemodynamic response to dexmedetomidine. Mean arterial pressure primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Arrhythmias.</measure>
    <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
    <description>Presence of arrhythmias was studied using a 3 lead realtime EKG throughout study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
    <description>Pulse oximetry was used to measure oxygen saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
    <description>Heart Rate recorded off EKG in beats per minute</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Burns</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Ascending dose study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses of dexmedetomidine (as per protocol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.</description>
    <arm_group_label>Ascending dose study</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric patient

          -  &gt;25% total body surface area (tbsa) burn and &lt; 90% tbsa

          -  opioid requirements &gt; 0.1 mg/kg/hour of morphine (or equivalent)

          -  midazolam requirement &gt; 0.1 mg/kg/hour

          -  treatment team determined that patient should be started on dexmedetomidine

        Exclusion Criteria:

          -  hemodynamically unstable patients (epinephrine &gt; 1.0 ug/kg/min, levophed &gt; 0.75
             ug/kg/min, dopamine &gt; 10 ug/kg/min)

          -  pregnant patients

          -  patients with history of heart block

          -  patients with congenital heart disease

          -  patients with significant hepatic dysfunction

          -  patients with urine output &lt; 0.5 ml/kg/hour [averaged] over past 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik S Shank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Burn Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2017</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Erik S. Shank, MD</investigator_full_name>
    <investigator_title>Pediatric Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>burn</keyword>
  <keyword>sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
          <description>All participants received a dexmedetomidine bolus of 1.0 micrograms (mcg) per kilogram over 10 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Dexmedetomidine 0.7 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and a continuous infusion for 15 minutes of 0.7 mcg/kg/hr of dexmedetomidine. This group is a subset of Cohort 1 that continued in this ascending dose study.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose, followed by dexmedetomidine infusion for 15 minutes at 0.7 mcg/kg/hr, followed by 1.0 mcg/kg/hr infusion for 15 minutes. This is a subset of cohort 2.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: Dexmedetomidine Infusion 1.3 mcg/kg/hr</title>
          <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes. This group is a subset of cohort 3.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes. This group is a subset of cohort 4.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr</title>
          <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes. This group is a subset of cohort 5.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr</title>
          <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes. This group is a subset of cohort 6.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr</title>
          <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes, followed by 2.5 mcg/kg/hr over 15 minutes. This group is a subset of cohort 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dexmedetomidine Bolus 1 mcg/kg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0">One participant did not begin infusion due to hypotension (mean pressure &lt;50)</participants>
                <participants group_id="P3" count="0">2 participants did not begin the ascending (1.0 mcg/kg/hr) due to MAP&lt;50</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine 0.7 mcg/kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7">1 participant did not begin infusion due to hypotension (MAP&lt;50)</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3">2 participants did not begin this infusion due to hypotension (MAP&lt;50)</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine 1.3 mcg.kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine 1.6 mcg.kg.hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dexmedetomidine 1.9 mcg/kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine 2.2 mcg/kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine 2.5 mcg/kg/hr Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ascending Dose Study</title>
          <description>Ascending doses of dexmedetomidine (as per protocol)
Dexmedetomidine: Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Body Surface Area Burned</title>
          <units>percentage of surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Venous Pressure</title>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time after injury in days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fluid intake-Fluid output</title>
          <units>ml/kg/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.7" spread="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Mean Arterial Pressure (MAP)</title>
        <description>Looking at hemodynamic response to dexmedetomidine. Mean arterial pressure primary outcome measure.</description>
        <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
        <population>Acutely burned pediatric patients intubated with burns &gt;=20% between 2 and 19 years of age requiring escalating doses of morphine and midazolam</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Dexmedetomidine Bolus + 0.7 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Dexmedetomidine Infusion 1.3 mcg/kg/hr</title>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr</title>
          </group>
          <group group_id="O7">
            <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr</title>
          </group>
          <group group_id="O8">
            <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Mean Arterial Pressure (MAP)</title>
          <description>Looking at hemodynamic response to dexmedetomidine. Mean arterial pressure primary outcome measure.</description>
          <population>Acutely burned pediatric patients intubated with burns &gt;=20% between 2 and 19 years of age requiring escalating doses of morphine and midazolam</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="7.5"/>
                    <measurement group_id="O2" value="30.8" spread="10.2"/>
                    <measurement group_id="O3" value="26.5" spread="10.5"/>
                    <measurement group_id="O4" value="24.5" spread="13.8"/>
                    <measurement group_id="O5" value="25.5" spread="12.5"/>
                    <measurement group_id="O6" value="18" spread="8.7"/>
                    <measurement group_id="O7" value="15" spread="7"/>
                    <measurement group_id="O8" value="15.6" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Arrhythmias.</title>
        <description>Presence of arrhythmias was studied using a 3 lead realtime EKG throughout study.</description>
        <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
        <population>EKG was analyzed on each participant looking for presence of arrhythmias. None were detected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
            <description>Ascending doses of dexmedetomidine (as per protocol)
Dexmedetomidine: Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Dexmedetomidine Bolus + 0.7 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Dexmedetomidine Infusion 1.3 mcg/kg/hr</title>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr</title>
          </group>
          <group group_id="O7">
            <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr</title>
          </group>
          <group group_id="O8">
            <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr</title>
          </group>
        </group_list>
        <measure>
          <title>Presence of Arrhythmias.</title>
          <description>Presence of arrhythmias was studied using a 3 lead realtime EKG throughout study.</description>
          <population>EKG was analyzed on each participant looking for presence of arrhythmias. None were detected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation</title>
        <description>Pulse oximetry was used to measure oxygen saturation.</description>
        <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
            <description>All participants received a dexmedetomidine bolus of 1.0 micrograms (mcg) per kilogram over 10 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Dexmedetomidine 0.7 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dexmedetomidine and a continuous infusion for 15 minutes of 0.7 mcg/kg/hr of dexmedetomidine. This group is a subset of Cohort 1 that continued in this ascending dose study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dose, followed by dexmedetomidine infusion for 15 minutes at 0.7 mcg/kg/hr, followed by 1.0 mcg/kg/hr infusion for 15 minutes. This is a subset of cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Dexmedetomidine Infusion 1.3 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes. This group is a subset of cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes. This group is a subset of cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes. This group is a subset of cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes. This group is a subset of cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes, followed by 2.5 mcg/kg/hr over 15 minutes. This group is a subset of cohort 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation</title>
          <description>Pulse oximetry was used to measure oxygen saturation.</description>
          <units>Percent of Hemoglobin Saturated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="0.5"/>
                    <measurement group_id="O2" value="99.5" spread="0.8"/>
                    <measurement group_id="O3" value="99.5" spread="0.8"/>
                    <measurement group_id="O4" value="98.6" spread="1.1"/>
                    <measurement group_id="O5" value="98.6" spread="1.1"/>
                    <measurement group_id="O6" value="98.6" spread="1.3"/>
                    <measurement group_id="O7" value="99.3" spread="1.5"/>
                    <measurement group_id="O8" value="99.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Heart Rate recorded off EKG in beats per minute</description>
        <time_frame>10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
            <description>All participants received a dexmedetomidine bolus of 1.0 micrograms (mcg) per kilogram over 10 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Dexmedetomidine 0.7 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dexmedetomidine and a continuous infusion for 15 minutes of 0.7 mcg/kg/hr of dexmedetomidine. This group is a subset of Cohort 1 that continued in this ascending dose study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dose, followed by dexmedetomidine infusion for 15 minutes at 0.7 mcg/kg/hr, followed by 1.0 mcg/kg/hr infusion for 15 minutes. This is a subset of cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Dexmedetomidine Infusion 1.3 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes. This group is a subset of cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes. This group is a subset of cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes. This group is a subset of cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes. This group is a subset of cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr</title>
            <description>This group received the bolus dose followed by the ascending infusion first at 0.7 mcg/kg/hr for 15 minutes, then 1.0 mcg/kg/hr for 15 minutes, the 1.3 mcg/kg.hr for 15 minutes, followed by 1.6 mcg/kg/hr for 15 minutes, followed by 1.9 mcg/kg/hr for 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes, followed by 2.5 mcg/kg/hr over 15 minutes. This group is a subset of cohort 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart Rate recorded off EKG in beats per minute</description>
          <units>heart beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.6" spread="16.6"/>
                    <measurement group_id="O2" value="122" spread="15.8"/>
                    <measurement group_id="O3" value="127.5" spread="11.9"/>
                    <measurement group_id="O4" value="125.5" spread="17.2"/>
                    <measurement group_id="O5" value="122.8" spread="17.8"/>
                    <measurement group_id="O6" value="129.7" spread="11.6"/>
                    <measurement group_id="O7" value="132.3" spread="17.9"/>
                    <measurement group_id="O8" value="125" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for the two hour period of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Dexmedetomidine Bolus 1 mcg/kg Over 10 Min IV</title>
          <description>All participants received a dexmedetomidine bolus dose of 1 microgram/kilogram over 10 minutes IV</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: Dexmedetomidine 0.7 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: Dexmedetomidine 1.0 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: Dexmedetomidine 1.3 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes, followed by 1.3 mcg/kg/hr</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5: Dexmedetomidine 1.6 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes, followed by 1.3 mcg/kg/hr, followed by 1.6 mcg/kg/hr over 15 minutes</description>
        </group>
        <group group_id="E6">
          <title>Cohort 6: Dexmedetomidine 1.9 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes, followed by 1.3 mcg/kg/hr, followed by 1.6 mcg/kg/hr over 15 minutes, followed by 1.9 mcg/kg/hr over 15 minutes</description>
        </group>
        <group group_id="E7">
          <title>Cohort 7: Dexmedetomidine 2.2 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes, followed by 1.3 mcg/kg/hr, followed by 1.6 mcg/kg/hr over 15 minutes, followed by 1.9 mcg/kg/hr over 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes</description>
        </group>
        <group group_id="E8">
          <title>Cohort 8: Dexmedetomidine 2.5 mcg/kg/hr Infusion</title>
          <description>This group received the bolus dose and then an infusion of 0.7 mcg/kg/hr for 15 minutes, followed by 1.0 mcg/kg/hr over 15 minutes, followed by 1.3 mcg/kg/hr, followed by 1.6 mcg/kg/hr over 15 minutes, followed by 1.9 mcg/kg/hr over 15 minutes, followed by 2.2 mcg/kg/hr over 15 minutes, followed by 2.5 mcg/kg/hr over 15 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>hypotension</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Significant hypotension defined as mean arterial pressure &lt;50 mm Hg</sub_title>
                <description>Hypotension, defined as mean arterial pressure (MAP) &lt; 50 millimeters of mercury, was considered an adverse event and would halt the ascending dose study for the subject.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erik Shank, MD</name_or_title>
      <organization>Mass General Hospital for Children</organization>
      <phone>6177242250</phone>
      <email>eshank@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

